Stage 3 melanoma attacked with immunotherapy and a virus-like particleNovember 28, 2022MelanomaOncology
Findings may be practice changing for early breast cancer patientsOctober 31, 2022OncologyBreast Cancer
Atezolizumab doubles survival of NSCLC patients with poor performance statusSeptember 19, 2022Lung CancerOncology
A farewell to arms? Drug approvals based on single-arm trials can be flawedSeptember 19, 2022OncologyMixed TopicsBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLung CancerMelanoma
